KYMR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Positive Phase 1 Trial Results for KT-579

Oct 29, 2026

8-K

Kymera Therapeutics Reports Q2 2026 Financial Results and Pipeline Progress

Aug 5, 2026

8-K

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Jul 27, 2026

8-K

Kymera Therapeutics Completes Enrollment in Phase 2b BROADEN2 Trial of KT-621

Jun 25, 2026

8-K

Kymera Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Shareholders

Jun 24, 2026

8-K

Kymera Therapeutics Announces Resignation of Chief Operating Officer Jeremy Chadwick

Jun 8, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Feb 26, 2026

424B5

February 2026 ATM | Offering amount: $500,000,000 | Bank: TD Cowen

Feb 26, 2026

424B5

FIXED PRICE OFFERING - COMMON STOCK | Offering amount: $602,000,000 | Shares: 7,000,000 | Price: $86.000 | Bank: Morgan Stanley

Dec 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $500,000,000 | Bank: Morgan Stanley

Dec 8, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jun 27, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jun 25, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8